logo-loader
viewSynairgen PLC

Synairgen chief delighted with amended fibrosis collaboration deal

Richard Marsden, chief executive of Synairgen plc (LON:SNG), tells Proactive they've handed responsibility for their fibrosis treatment programme to Pharmaxis (ASX:PXS) in return for a payment of £5mln and 17% of any future partnership agreement.

The two companies have been collaborating on the development of a Lysyl Oxidase type 2 (LOXL2) inhibitor (PXS-5382) to treat lung and liver fibrosis.

Quick facts: Synairgen PLC

Price: 7.625 GBX

AIM:SNG
Market: AIM
Market Cap: £8.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen's phase II trial on lead COPD drug 'progressing well'

Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott  the respiratory drug discovery and development company, is well-poised to complete the phase II trial on its lead candidate. The trial is expected to complete dosing in Q1 next year with results available in...

on 30/9/19

2 min read